Leerink Partnrs Estimates enGene FY2030 Earnings

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at Leerink Partnrs issued their FY2030 earnings estimates for shares of enGene in a research report issued on Tuesday, November 11th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn $1.42 per share for the year. The consensus estimate for enGene's current full-year earnings is ($1.56) per share.enGene (NASDAQ:ENGN - Get Free Report) last issued its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Other equities research analysts have also recently issued research reports about the stock. Raymond James Financial raised shares of enGene from an "outperform" rating to a "strong-buy" rating and set a $27.00 target price for the company in a research report on Tuesday. Oppenheimer reaffirmed an "outperform" rating and set a $33.00 target price (up from $30.00) on shares of enGene in a report on Wednesday. UBS Group boosted their price target on enGene from $4.00 to $10.00 and gave the company a "neutral" rating in a research note on Wednesday. Citizens Jmp raised their price objective on enGene from $18.00 to $21.00 and gave the stock a "market outperform" rating in a research note on Wednesday. Finally, Citigroup reaffirmed a "market outperform" rating on shares of enGene in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $22.38.Get Our Latest Stock Analysis on enGeneenGene Stock PerformanceNASDAQ ENGN traded down $0.15 on Thursday, reaching $8.54. The stock had a trading volume of 1,591,035 shares, compared to its average volume of 393,891. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The company has a market cap of $436.91 million, a P/E ratio of -4.52 and a beta of -0.27. The firm has a fifty day moving average of $7.20 and a two-hundred day moving average of $4.95. enGene has a 1-year low of $2.65 and a 1-year high of $11.14. Institutional Trading of enGeneSeveral hedge funds have recently modified their holdings of ENGN. Cresset Asset Management LLC bought a new position in shares of enGene during the 2nd quarter worth about $36,000. Paloma Partners Management Co acquired a new stake in enGene in the second quarter valued at approximately $38,000. PFS Partners LLC bought a new stake in shares of enGene during the third quarter valued at approximately $61,000. ADAR1 Capital Management LLC bought a new position in shares of enGene in the 1st quarter worth $107,000. Finally, Affinity Asset Advisors LLC acquired a new stake in enGene in the 2nd quarter valued at $280,000. Institutional investors own 64.16% of the company's stock. About enGene (Get Free Report)enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.See AlsoFive stocks we like better than enGeneWhat is a Dividend King? AMD to $300 Looks Easy—Here’s Why $500 Could Be NextThe Basics of Support and Resistance$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You Compound Interest and Why It Matters When Investing4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in enGene Right Now?Before you consider enGene, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here